• organizations:Bausch + Lomb
Phase 4 data presents early patient-reported outcomes of MIEBO
Pipeline

Phase 4 data presents early patient-reported outcomes of MIEBO

Study finds symptom relief achieved as early as 5 to 60 minutes on day 1 of dosing—with significant reduction in overall severity after 14 days.
KALAHARI phase 3 extension trial data published on MIEBO
Research

KALAHARI phase 3 extension trial data published on MIEBO

Long-term safety and efficacy results on the prescription eye drop published in Cornea.
Bausch + Lomb launches MIEBO in the US
Products

Bausch + Lomb launches MIEBO in the US

Preservative-free eye drop is the first and only approved DED treatment that directly targets tear evaporation.
Bausch + Lomb and Novaliq receive FDA approval for MIEBO to treat DED
Products

Bausch + Lomb and Novaliq receive FDA approval for MIEBO to treat DED

Formerly known as NOV03, the ophthalmic solution is now the first and only approved DED treatment directly targeting tear evaporation.
Bausch + Lomb, Novaliq release second phase 3 data for NOV03
Pipeline

Bausch + Lomb, Novaliq release second phase 3 data for NOV03

Results from MOJAVE study support potential for treating DED associated with MGD.
Are there any new treatments for dry eye? — Weekly Glance
Archives

Are there any new treatments for dry eye? — Weekly Glance

An eye drop to treat MGD is on the horizon. — Weekly Glance
Archives

An eye drop to treat MGD is on the horizon. — Weekly Glance

Bausch + Lomb and Novaliq just submitted an NDA for NOV03, an eye drop that treats the signs and symptoms of dry eye disease associated with meibomian gland dysfunction (MGD).